ArticleMaterials today. Bio2025
Stabilization of metal-doped magnesium oxide nanoparticles with PAMAM dendrimers to improve alpha-amylase enzyme inhibition.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- NiRSC advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study aimed to synthesize metal-doped magnesium oxide (MgO) nanoparticles to drastically reduce polydispersity and stabilize them with generation 5 of poly(amidoamine) (G5 PAMAM) dendrimers to assess their antidiabetic properties via controlled release. Zinc and silver metals were selected as dopants due to their ionic radius (0.74 Å and 1.16 Å, respectively) for MgO crystal defect reduction (ionic radii - 0.72 Å), allowing for the comparison of the dopants' effect on the nanoparticles' properties. Later, the resultant nanoparticles were formulated into G5 PAMAM dendrimers, and their amylase inhibition was evaluated and compared with that of non-formulated samples. The results showed that the addition of dopants led to smaller, more stable, and slightly monodispersed spherical, hexagonal, and elongated hexagonal/rod-shaped MgO nanoparticles. The smaller size (∼11-72 nm), surface charge (ca. 17-24 mV), crystallite size ranging from 9.07 nm (Zn-doped MgO) to 17.44 nm (Ag-doped MgO), and distinct shapes have led to enhanced stabilization via G5 dendrimer. Notably, unlike other shapes, spherical nanoparticles were highly stabilized by dendrimers because of the absence of edged atoms. Amylase inhibition assay revealed that dendrimer-stabilized zinc-doped MgO nanoparticles exhibited enhanced inhibitory activity (82.9 %) at 0 h, which decreased to 66.6 % after 24 h, indicating controlled nanoparticle release by the dendrimer. Therefore, this study confirmed the significant role of dendrimer-stabilized metal-doped MgO nanoparticles in enhancing their ability to inhibit enzymes in a controlled manner. These findings led to a novel mechanism that has not been proposed in previous studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.